Chugai settles patent infringement litigation in USA
Japanese drug major Chugai Pharmaceutical (TYO: 4519) announced that, along with majority owner Roche (ROG: SIX) and its biotech subsidiary Genentech (collectively “the companies”) have entered into a settlement agreement with Fresenius Kabi USA, on August 5, 2022 relating to the patent lawsuit filed by the companies on March 19, 2020.
In the lawsuit, the companies alleged that the submission of an Abbreviated New Drug Application (ANDA) by Fresenius for a generic version of Alecensa (alectinib), an ALK inhibitor, anti-cancer agent, to the US Food and Drug Administration infringed Chugai’s patents in the USA (Nos 9,126,931; 9,440,922; 9,365,514 and 10,350,214) under the framework of the Drug Price Competition and Patent Term Restoration Act (known as Hatch-Waxman Act).
In accordance with the settlement agreement, the companies and Fresenius will take steps to withdraw the lawsuit.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze